Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 2, 2004, Pages 405-413

  Overstreet, David H ^a   Knapp, Darin J ^a   Breese, George R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; CP 154,526; CRA1000; CRF; CRF1 receptors; Repeated ethanol withdrawal; Social interaction test

Indexed keywords

4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; RECEPTOR SUBUNIT; SAUVAGINE; UNCLASSIFIED DRUG;

ALCOHOL WITHDRAWAL; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DIET; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; SENSITIZATION; SOCIAL INTERACTION;

ANIMALIA;

EID: 1642452720     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.11.010     Document Type: Article

References (49)

1. Andrews N., File S.E., Fernandes C., Gonzalez L.E., Barnes N.M. Evidence that the median raphe nucleus-dorsal hippocampal pathway mediates diazepam withdrawal-induced anxiety. Psychopharmacology. 130:1997;228-234.
2. Archer J. Tests for emotionality in rats and mice. A review. Anim. Behav. 21:1973;205-235.
3. Barnes N.M., Costall B., Kelly M.E., Onaivi E.S., Naylor R.H. Ketotifen and its analogues reduce aversive responding in the rodent. Pharmacol. Biochem. Behav. 37:1990;785-793.
4. Battacharya S.K., Satyan K.S., Chakraharti A. Anxiogenic action of caffeine: an experimental study in rats. J. Psychopharmacol. 11:1997;219-224.
5. Blizard D.A., Adams N. The Maudsley reactive and nonreactive strains: a new perspective. Behav. Genet. 32:2002;277-299.
6. Brauns O., Liepold T., Radulovic J., Spiess J. Pharmacological and chemical properties of astressin, antisauvagine-30 and alpha-helCRF: significance for behavioral experiments. Neuropharmacology. 41:2001;507-516.
7. 1A receptor agonist. Neuropsychopharmacology online publication 10 July, 2003. Available at: http://www.acnp.org/citations/Npp07100303159/default.pdf .
8. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Onaivi E.S., Tyers M.B. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol. Biochem. Behav. 36:1990;339-344.
9. Driessen M., Meier S., Hill A. The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol Alcohol. 36:2001;249-255.
10. File S.E. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J. Neurosci. Methods. 2:1980;219-238.
11. File S.E., Hyde J.R. Can social interaction be used to measure anxiety? Br. J. Pharmacol. 62:1978;19-24.
12. File S.E., Lister R.G. Do the reductions in social interaction produced by picrotoxin and pentylenetetrazole indicate anxiogenic actions? Neuropharmacology. 23:1984;793-796.
13. File S.E., Seth P. A review of 25 years of the social interaction test. Eur. J. Pharmacol. 463:2003;35-53.
14. File S.E., Baldwin H.A., Hitchcot P.K. Flumazenil but not nitrendipine reverses the increased anxiety during alcohol withdrawal in the rat. Psychopharmacology. 98:1989;262-264.
15. Frye G.D., McCown T.J., Breese G.R. Differential sensitivity of alcohol withdrawal signs in the rat to γ-aminobutyric acid (GABA) mimetics: blockade of audiogenic seizures but not forelimb tremors. J. Pharmacol. Exp. Ther. 226:1983;720-725.
16. 1A receptor function: a link between anxiety and depression? Pharmacol. Biochem. Behav. 59:1998;787-792.
17. Guy A.P., Gardner C.R. Pharmacological characterisation of a modified social interaction model of anxiety in the rat. Neuropsychobiology. 13:1985;194-200.
18. Harro J., Tomissaar M., Eller M. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat. Neuropeptides. 35:2001;100-109.
19. 2, receptors mediate anxiogenic-like behavior. Regul. Pept. 71:1997;15-21.
20. Holter S.M., Engelmann M., Kirschke C., Liebsch G., Landgraf R., Spanagel R. Long-term ethanol self-administration with repeated ethanol deprivation episodes changes ethanol drinking pattern and increases anxiety-related behaviour during ethanol deprivation in rats. Behav. Pharmacol. 9:1998;41-48.
21. Irvine E.E., Bagnalasta M., Marcon C., Motta C., Tessari M., File S.E.et al. Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats. Psychopharmacology. 153:2001;315-320.
22. Kampov-Polevoy A.B., Matthews D.B., Gause L., Morrow A.L., Overstreet D.H. P rats develop physical dependence on alcohol via voluntary drinking: changes in seizure thresholds, anxiety, and patterns of alcohol drinking. Alcohol. Clin. Exp. Res. 24:2000;278-284.
23. Keck M.E., Holsboer F. Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides. 22:2001;835-844.
24. Keck M.E., Welt T., Wigger A., Renner U., Englemann M., Holsboer F.et al. The anxiolytic effect of the CRH (1) receptor antagonist R 121919 depends on innate emotionality in rats. Eur. J. Pharmacol. 13:2001;373-380.
25. 1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr. Drug Targets CNS Neurol. Disord. 1:2002;467-493.
26. Knapp D.J., Duncan G.E., Crews F.T., Breese G.R. Induction of Fos-like proteins and ultrasonic vocalizations during ethanol withdrawal: further evidence for withdrawal-induced anxiety. Alcohol. Clin. Exp. Res. 22:1998;481-493.
27. Knapp D.J., Overstreet D.H., Breese G.R. SB242084, flumazenil, and CRA1000 block ethanol withdrawal anxiety in rats. Alcohol. 2004;. [in press].
28. Koob G.F., Roberts A.J., Schulteis G., Parsons L.H., Heyser C.J., Hyytia P.et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol. Clin. Exp. Res. 22:1998;3-9.
29. Landgraf R. Neuropeptides and anxiety-related behavior. Endocr. J. 48:2001;517-533.
30. Landgraf R., Wigger A. High v low anxiety-related behavior rats. An animal model of extremes in trait anxiety. Behav. Genet. 32:2002;301-314.
31. Le A.D., Harding S., Juzytch W., Watchus J., Shalev U., Shamam Y. The role of corticotropin releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology. 150:2000;317-324.
32. Lightowler S., Kennett G.A., Williamson U., Blackburn T.P., Tulloch I.F. Anxiolytic-like effect of paroxetine in the rat social interaction test. Pharmacol. Biochem. Behav. 49:1994;281-285.
33. Malcolm R., Roberts J.-S., Wang W., Myrick H., Anton R.F. Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification. Alcohol. 22:2000;159-164.
34. McCown T.J., Breese G.R. Multiple withdrawals from chronic ethanol "kindles" inferior collicular seizure activity: evidence for kindling of seizures associated with alcoholism. Alcohol. Clin. Exp. Res. 14:1990;394-399.
35. Menzaghi F., Rassnick S., Heinrich S., Baldwin H., Pich E.M., Weiss F.et al. The role of corticotropin releasing factor in the anxiogenic effects of ethanol withdrawal. Ann. N. Y. Acad. Sci. 739:1994;176-184.
36. Moy S.S., Knapp D.J., Criswell H.E., Breese G.R. Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology. 131:1997;354-360.
37. Moy S.S., Knapp D.J., Duncan G.E., Breese G.R. Enhanced ultrasonic vocalization and Fos protein expression following ethanol withdrawal: effects of flumazenil. Psychopharmacology. 152:2000;208-215.
38. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Nakazato A.et al. Receptor binding, behavioral, and electrophysiological profiles of non-peptide corticotropin-releasing factor subtype1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 289:1999;926-935.
39. Overstreet D.H., Knapp D.J., Breese G.R. Accentuated decreases in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol. Clin. Exp. Res. 26:2002;1259-1269.
40. 2C antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology. 167:2003;344-352.
41. Radulovic J., Ruhmann A., Leopold T., Spiess J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress; differential roles of CRF receptors 1 and 2. J. Neurosci. 19:1999;5016-5025.
42. Rasmussen D.D., Boldt B.M., Bryant C.A., Mitton D.R., Larsen S.A., Wilkinson C.W. Chronic daily ethanol and withdrawal: 1. Long-term changes in the hypothalamo-pituitary-adrenal axis. Alcohol. Clin. Exp. Res. 24:2000;1836-1849.
43. Rassnick S., Heinrichs S.C., Britton K.T., Koob G.F. Microinjection of corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605:1993;25-32.
44. Rivier C., Lee S. Effect of repeated exposure to alcohol on the response of the hypothalamic-pituitary-adrenal axis of the rat: II. Role of the length and regimen of alcohol treatment. Alcohol. Clin. Exp. Res. 25:2001;106-111.
45. Sams-Dodd F. Automation of the social interaction test by a video-tracking system: behavioral effects of repeated phencyclidine treatment. J. Neurosci. Methods. 1995;157-167.
46. 1 receptor. A review. CNS Drug Rev. 9:2003;57-96.
47. Sinha R. How does stress increase risk of drug abuse and relapse? Psychopharmacology. 158:2001;343-359.
48. Spina M.G., Merlo-Pich E., Akwa Y., Balducci C., Basso A.M., Zorrilla E.P.et al. Time-dependent induction of anxiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. Psychopharmacology. 160:2002;113-121.
49. Valdez G.R., Zorrilla E.P., Roberts A.J., Koob G.F. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol. 29:2003;55-60.